NCI’s Molecular Profiling to Predict Response to Treatment (MP2PRT) Program to characterize samples collected from NCI-sponsored clinical trials in order to help predict which therapies will benefit specific patients. This first batch of data contains Wilms Tumor samples.
DR 33 also includes additional methylation data for TARGET and CGCI programs. For details, please visit the GDC Data Release Notes.